XM اپنی سروسز امریکہ کے شہریوں کو فراہم نہیں کرتا ہے۔
P
P

Pfizer


خبر

For global firms, India IPOs are a honey trap

RPT-BREAKINGVIEWS-For global firms, India IPOs are a honey trap The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Una Galani MUMBAI, Sept 17 (Reuters Breakingviews) - It rarely makes sense for a company to maintain more than one stock market listing. Tell that to the growing list of multinational firms rushing to float their local subsidiaries on Mumbai bourses.
C
N
P

Evonik sees 1.5-bln-euro boost to sales by 2032 with new strategy

Evonik sees 1.5-bln-euro boost to sales by 2032 with new strategy Sept 17 (Reuters) - German chemicals group Evonik Industries EVKn.DE is targeting 1.5 billion euros ($1.67 billion) in additional sales by 2032 under a new innovation strategy, the company said on Tuesday. The strategy seeks to bundle a large proportion of Evonik's research and development activities in three new innovation growth areas, listed in a statement as bio-based solutions, the energy transition and the circular economy.
P

For global firms, India IPOs are a honey trap

BREAKINGVIEWS-For global firms, India IPOs are a honey trap The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Una Galani MUMBAI, Sept 17 (Reuters Breakingviews) - It rarely makes sense for a company to maintain more than one stock market listing. Tell that to the growing list of multinational firms rushing to float their local subsidiaries on Mumbai bourses.
C
N
P

Vista, Blackstone nearing $8-billion deal to buy Smartsheet, sources say

EXCLUSIVE-Vista, Blackstone nearing $8-billion deal to buy Smartsheet, sources say By Milana Vinn and Mike Spector NEW YORK, Sept 16 (Reuters) - Buyout firms Vista Equity Partners and Blackstone BX.N are in advanced talks to acquire Smartsheet SMAR.N , in a deal that could value the collaboration-software maker at close to $8 billion, people familiar with the matter said on Monday.
C
P

U.S. STOCKS Charles Schwab, CACI International, Icahn Enterprises

BUZZ-U.S. STOCKS ON THE MOVE-Charles Schwab, CACI International, Icahn Enterprises Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Technology stocks weighed on the S&P 500 and the Nasdaq on Monday as caution set in ahead of the Federal Reserve's pivotal monetary policy decision, due later in the week, with a majority of traders pricing in a steep reduction in borrowing costs.
A
C
I
P
Q
S
L
W
U
U
E

U.S. STOCKS Bausch + Lomb, Alcoa, crypto stocks

BUZZ-U.S. STOCKS ON THE MOVE-Bausch + Lomb, Alcoa, crypto stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The main U.S. stock indexes were set for a mixed open on Monday as caution set in on Wall Street ahead of the Federal Reserve's pivotal monetary policy decision, due later in the week, with a majority of traders pricing in a steep cut in borrowing costs.
A
I
P
L
W
U
E

U.S. STOCKS Intel, Colgate-Palmolive, Zillow Group

BUZZ-U.S. STOCKS ON THE MOVE-Intel, Colgate-Palmolive, Zillow Group Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures were subdued on Monday as caution prevailed ahead of the Federal Reserve's pivotal monetary policy decision later in the week, with investors pricing in a steep reduction in borrowing costs.
A
I
P
U

Pfizer's mid-stage cancer drug data at ESMO 'intriguing', Guggenheim says

BUZZ-Pfizer's mid-stage cancer drug data at ESMO 'intriguing', Guggenheim says ** Brokerage Guggenheim notes mid-stage data for Pfizer's PFE.N ponsegromab in cancer cachexia to be "intriguing"; says could lead to increased investor interest ahead of mid-stage data in heart failure expected next year ** PFE at the European Society for Medical Oncolo
P

Pfizer Presents Positive Data From Phase 2 Study Of Ponsegromab In Patients With Cancer Cachexia

BRIEF-Pfizer Presents Positive Data From Phase 2 Study Of Ponsegromab In Patients With Cancer Cachexia Sept 14 (Reuters) - Pfizer Inc PFE.N : PFIZER PRESENTS POSITIVE DATA FROM PHASE 2 STUDY OF PONSEGROMAB IN PATIENTS WITH CANCER CACHEXIA PFIZER - STUDY MET PRIMARY ENDPOINT OF CHANGE FROM BASELINE IN BODY WEIGHT FOR PONSEGROMAB COMPARED TO PLACEBO
P

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi By Michael Erman NEW YORK, Sept 14 (Reuters) - Pfizer PFE.N is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates could grow to become the standard of care. The company presented three-year follow-up data from a Phase 2 study on Saturday looking at patients with BRAF V600E-mutant metastatic non-small cell l
P

US FDA approves Eli Lilly's drug for eczema

UPDATE 2-US FDA approves Eli Lilly's drug for eczema Adds details on disease in paragraph 3, patient population in paragraph 6, other treatments in paragraphs 7-8, details on drug in paragraphs 8-9 Sept 13 (Reuters) - Eli Lilly LLY.N said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.
P
R
S

Roche shares knocked by concern over side effects in obesity pill trial

UPDATE 1-Roche shares knocked by concern over side effects in obesity pill trial Roche shares fall 3.5% Early study trial showed high rate of temporary side effects JP Morgan analysts say heart rate increase is as a concern Roche plans slower ramp-up of pill dose in next trial Updates share price in paragraph 2, further details on side effects in pill trial in paragraphs 6 and 8 FRANKFURT, Sept 12 (Reuters) - Shares in Roche ROG.S dropped to a two-month low on Thursday after an experimental weig
J
P
R

Antifungal drug developer F2G raises $100 mln to fight 'superbugs', fund late-stage trial

Antifungal drug developer F2G raises $100 mln to fight 'superbugs', fund late-stage trial By Kashish Tandon Sept 12 (Reuters) - F2G said on Thursday it has raised $100 million from investors including AMR Action Fund, backed by large drugmakers such as Johnson & Johnson and Pfizer, to help it develop treatments for infections caused by drug resistant "superbugs" or microbes.
G
P

Moderna forecasts lower sales next year, shares slide to four-year low

UPDATE 4-Moderna forecasts lower sales next year, shares near four-year low Adds executive comment in paragraph 7 By Patrick Wingrove Sept 12 (Reuters) - Moderna MRNA.O pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted 2025 sales below its forecast for the current year, sending its shares closer to a four-year low.
P
S

Moderna expects up to $3.5 billion in 2025 sales

Moderna expects up to $3.5 billion in 2025 sales By Patrick Wingrove Sept 12 (Reuters) - Moderna MRNA.O on Thursday said it expects sales of between $2.5 billion and $3.5 billion next year, and forecast that new product launches would drive an average annual growth rate of 25% in revenue between 2026 and 2028. The vaccine maker last month projected sales of $3 billion and $3.5 billion for this year, which will be its lowest annual revenue since Moderna launched its COVID-19 vaccine in late 2020
P
S

Roche shares drop on side effects result in early-stage obesity pill trial

Roche shares drop on side effects result in early-stage obesity pill trial FRANKFURT, Sept 12 (Reuters) - Shares in Roche ROG.S fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans. Roche shares were down 4% at the open at 0700 GMT after the company presented late on Wednesday details on the trial .
P
R

Roche says early-stage obesity pill results were based on just six patients

UPDATE 1-Roche says early-stage obesity pill results were based on just six patients Adds detail of trial in paragraph 6, company comment in paragraph 7, further detail in paragraphs 8-10 FRANKFURT, Sept 11 (Reuters) - Roche ROG.S said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.
P
R

Roche says early-stage obesity pill results were based on just six patients

Roche says early-stage obesity pill results were based on just six patients FRANKFURT, Sept 11 (Reuters) - Roche ROG.S said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project. The Swiss drugmaker said in July that the once-daily pill CT-996 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patie
P
R

Weight-loss market to see 16 new drugs by 2029, report estimates

Weight-loss market to see 16 new drugs by 2029, report estimates Sept 10 (Reuters) - The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N , according to estimates from analysts at Morningstar and Pitchbook. In a joint report published on Monday, analysts estimated the market for obesity treatments could expand to $200 billion by 2031. The 16 drugs could launch by 2029, wi
A
P
R

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year By Patrick Wingrove Sept 10 (Reuters) - UnitedHealth Group UNH.N said on Tuesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.
A
C
P
T



شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔